Hunter Associates Investment Mana.. recently announced the acquisition of new stake in Trinity Biotech plc (NASDAQ:TRIB). The institutional investor has increased its shareholding in the Healthcare company by 6.88% to 1.67 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 7.97% valued currently at $4.15 million. In addition, Renaissance Technologies LLC raised its holdings by 0.7 million to 1.58 million shares. And Morgan Stanley & Co. LLC has lifted its position by 232.32% or 0.13 million shares – to 0.19 million shares.
With over 1.45 million Trinity Biotech plc (TRIB) shares trading Tuesday and a closing price of $2.06 on the day, the dollar volume was approximately $2.99 million. The shares have shown a positive weekly performance of 0.98% and its price on 08/25/20 gained nearly 22.62%. Currently, there are 20.90M common shares owned by the public and among those 18.99M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for TRIB have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $5.00 should the stock experience a downside. But an upside of 58.8% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.
The top 3 mutual fund holders in Trinity Biotech plc are Heartland Group Inc. – Value Fund, Adirondack Small Cap Fund, and Paradice Global Small Cap Fund. Heartland Group Inc. – Value Fund owns 0.85 million shares of the company’s stock, all valued at over $2.12 million. Adirondack Small Cap Fund sold 62631.0 shares to see its total holdings shrink to 0.35 million shares valued at over $0.88 million and representing 1.69% of the shares outstanding. Paradice Global Small Cap Fund now owns shares totaling to 1.59% of the shares outstanding.
Shares of Trinity Biotech plc (NASDAQ: TRIB) opened at $1.65, down -$0.03 from a prior closing price of $1.68. However, the script later closed the day at $2.06, up 22.62%. The company’s stock has a 5-day price change of 0.98% and 59.69% over the past three months. TRIB shares are trading 99.34% year to date (YTD), with the 12-month market performance up to 47.14% higher. It has a 12-month low price of $0.56 and touched a high of $3.28 over the same period. Currently, 1.45 million shares have been traded, compared to an average intraday trading volume of 1.01 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.63%, -14.78%, and 41.44% respectively.
Institutional ownership of Trinity Biotech plc (NASDAQ: TRIB) shares accounts for 31.10% of the company’s 20.90M shares outstanding. Mutual fund holders own 27.34%, while other institutional holders and individual stakeholders account for 9.16% and — respectively.
It has a market capitalization of $56.46M and a beta (3y monthly) value of 1.74. The earnings-per-share (ttm) stands at -$1.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.84% over the week and 11.61% over the month.
Analysts forecast that Trinity Biotech plc (TRIB) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0.3 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was $0.04 a year ago. Earnings per share for the fiscal year are expected to decrease by -28.00%, and 100.00% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to -33.30% over the past 5-year period.
Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TRIB, a number of firms have released research notes about the stock. Craig Hallum stated their Hold rating for the stock in a research note on October 23, 2015, with the firm’s price target at. Raymond James coverage for the Trinity Biotech plc (TRIB) stock in a research note released on September 03, 2015 offered a Outperform rating with a price target of. ROTH Capital was of a view on July 29, 2015 that the stock is Buy, while Roth Capital gave the stock Buy rating on July 22, 2008, issuing a price target of $7- $6. Roth Capital on their part issued Buy rating on March 17, 2008.